Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00833963 · ClinicalTrials.gov registry record
A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine
A clinical trial, sponsored by Genentech.
- Completed
- Registry status
- 20
- Enrollment target
NCT00833963: Completed study, sponsored by Genentech.
NCT00833963 is a clinical trial that has completed, run by Genentech. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00833963 has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
The MotHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or ado-trastuzumab emtansine (kadcyla) during pregnancy or within 7 months prior to conception (regardless of cancer stage at the time of trastuzumab, pertuzumab, or ado-trastuzumab emtansine exposure).
Interventions
- DRUG Trastuzumab
- DRUG Pertuzumab
- DRUG Ado-Trastuzumab Emtansine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-01-14 |
| Est. Completion | 2017-04-13 |
What the finished NCT00833963 record still lists
NCT00833963 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 20 participants, a relatively small participant target.
The record links to 0 conditions, and to 3 interventions - of which Trastuzumab is the first listed.
NCT00833963 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00833963 about?
NCT00833963 is a clinical study titled "A Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Trastuzumab, Pertuzumab in Combination With Trastuzumab, or Ado-Trastuzumab Emtansine". The MotHER Pregnancy Registry is a United States (U.S.)-based, prospective, observational cohort study in women with breast cancer who have been or are being treated with a trastuzumab (herceptin)-containing regimen with or without pertuzumab (perjeta) or ado-trastuzumab emtansine (kadcyla) during p...
What is the current status of trial NCT00833963?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2009-01-14. Estimated completion is 2017-04-13.
What interventions are being tested in trial NCT00833963?
The interventions under investigation include: Trastuzumab (DRUG), Pertuzumab (DRUG), Ado-Trastuzumab Emtansine (DRUG).
Who is sponsoring clinical trial NCT00833963?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI